Post

New research · Hematology
The Korean journal of internal medicine · 23h
GuidelineThe Korean journal of internal medicine · 2026

Korean expert consensus on the management of thrombotic thrombocytopenic purpura.

Seo-Yeon Ahn, Junshik Hong, Jin Seok Kim … Korean Society of Hematology Thrombosis and Hemostasis Working Party and the Korean Society on Thrombosis and Hemostasis
Read paper
HematologyGuideline
“

Korean expert consensus on the management of thrombotic thrombocytopenic purpura.

Seo-Yeon Ahn et al. · The Korean journal of internal medicine · 2026
Background

Thrombotic thrombocytopenic purpura (TTP) is a rare but life-threatening thrombotic microangiopathy resulting from severe ADAMTS13 deficiency.

Purpose

By integrating international evidence with local circumstances, this document aims to provide Korean clinicians with practical, upto-date guidance to enhance the routine care of patients with TTP.

More results

Although effective treatments, such as therapeutic plasma exchange, immunosuppressive therapy with rituximab, and caplacizumab, have significantly improved survival, important challenges remain.

These include limited diagnostic capacity, barriers to the early use of novel therapies, and long-term complications.

More results

In Korea, additional difficulties persist due to the restricted availability of ADAMTS13 antibody testing, reimbursement limitations for rituximab, and the absence of caplacizumab in clinical practice.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
55.9% vs. 68.1%
Diabetic patients had lower major molecular response at 12 months (55.9% vs 68.1%).
Cohort Study
HR 2.59
sudden kidney damage meant over twice the risk of death for CAR-T recipients
Study
92.3%
Share of treated patients whose lymphoma shrank or cleared after treatment
Cohort Study
49%
Nearly half of patients had problems 30 days after spleen removal for blood cancer
Cohort Study
OR 3.95
flexible sigmoidoscopy makes it almost 4 times more likely to find gastrointestinal GvHD
Cohort Study
OR 3.8
Each additional low lab value associated with 3.8 times higher odds of Multisystem Inflammatory Syndrome in Children.
Cohort Study
adjusted hazard ratio 1.917
Patients with leukoerythroblastosis had a 1.9-fold higher hazard of 90-day death.
Cohort Study
30% higher risk
increased risk of new low blood cell counts per 0.1 g/L C3 decrease